NEW YORK, Feb. 17, 2026 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM) (Axsome), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today announced that it has entered into a settlement agreement with Alkem Laboratories Ltd. (Alkem) resolving patent litigation related to Axsome’s product SUNOSI® (solriamfetol). The litigation, which is pending in the United States District Court for the District of New Jersey, resulted from submission by A ...

Core Insights - Axsome Therapeutics, Inc. reported preliminary net product revenues for the fourth quarter and full year 2025, with total revenues expected to be $196.0 million and $638.5 million, reflecting annual growth rates of 65% and 66% respectively [2][3] Group 1: Financial Performance - AUVELITY is projected to generate net product sales of approximately $155.1 million for the fourth quarter and $507.1 million for the full year 2025 [6] - SUNOSI is expected to achieve net product revenue of around $36.7 million for the fourth quarter and $124.8 million for the full year 2025 [6] - SYMBRAVO is anticipated to have net product sales of about $4.1 million for the fourth quarter and $6.6 million for the full year 2025, following its commercial launch in June 2025 [6] Group 2: Company Overview - Axsome Therapeutics is focused on developing innovative treatments for central nervous system (CNS) disorders, with a portfolio that includes FDA-approved therapies for major depressive disorder, excessive daytime sleepiness, and migraines [4] - The company aims to address significant gaps in care and improve patient outcomes through differentiated products and novel mechanisms of action [4]

Core Insights - Axsome Therapeutics is actively participating in Mental Illness Awareness Week (MIAW) to promote mental health awareness and community support [1][2] - The theme for this year's MIAW is "Building Community: Supporting Mental Well-being Together," emphasizing the importance of grassroots advocacy and local action [1][2] - Axsome is committed to supporting individuals with mental health conditions and collaborates with organizations like NAMI to provide resources and reduce stigma [3][4] Company Overview - Axsome Therapeutics is a biopharmaceutical company focused on treating central nervous system (CNS) disorders, with a portfolio that includes FDA-approved treatments for major depressive disorder, narcolepsy, obstructive sleep apnea, and migraines [4] - The company aims to address critical gaps in care and develop innovative products that improve patient outcomes, impacting over 150 million people in the U.S. [4] - Axsome partners with national and global advocacy organizations to strengthen communities and provide support for those affected by mental health challenges [3][4] Mental Health Statistics - Over 1 in 5 adults in the U.S. experience mental illness each year, and more than 1 in 7 youth aged 6-17 also face mental health conditions annually [3] - Nearly 90% of individuals living with depression report difficulties in work, home, or social activities due to their symptoms, highlighting the significant impact of depression [3]

Core Viewpoint - Axsome Therapeutics, Inc. is set to report its financial results for Q3 2025 on November 3, 2025, before U.S. market opening, followed by a conference call for discussion [1] Company Overview - Axsome Therapeutics is a biopharmaceutical company focused on treating central nervous system (CNS) disorders, with a portfolio that includes FDA-approved treatments for major depressive disorder, excessive daytime sleepiness related to narcolepsy and obstructive sleep apnea, and migraine [3] - The company aims to address significant gaps in care by developing differentiated products with novel mechanisms of action, impacting over 150 million people in the U.S. [3] Financial Communication - A live conference call will be held at 8:00 a.m. Eastern Time on November 3, 2025, to discuss the financial results and provide a business update [1][2] - Participants can join the call via a toll-free domestic number or an international number, with a live webcast available on the company's website [2]

Core Viewpoint - Axsome Therapeutics, Inc. is set to report its financial results for Q2 2025 on August 4, 2025, before U.S. market opening, followed by a conference call for discussion [1] Company Overview - Axsome Therapeutics is a biopharmaceutical company focused on treating central nervous system (CNS) disorders, with a portfolio that includes FDA-approved treatments for major depressive disorder, excessive daytime sleepiness related to narcolepsy and obstructive sleep apnea, and migraine [3] - The company aims to address significant gaps in care by developing differentiated products with novel mechanisms of action, impacting over 150 million people in the U.S. [3] Financial Communication - The conference call to discuss financial results will take place at 8:00 a.m. Eastern Time, and a live webcast will be available on the company's website [2] - A replay of the conference call will be accessible for approximately 30 days post-event [2]

Core Insights - Axsome Therapeutics is collaborating with the Alzheimer's disease advocacy community to raise awareness about the increasing impact of Alzheimer's disease in the U.S. and the significance of brain health during Alzheimer's & Brain Awareness Month [1][2] Industry Overview - There are currently over 7 million Americans living with Alzheimer's disease, a number projected to rise to approximately 14 million by 2060 [2] - Alzheimer's disease is the most common form of dementia, characterized by cognitive decline and various behavioral symptoms [2] - Nearly 12 million individuals serve as caregivers for those affected by Alzheimer's disease, highlighting the extensive burden on public health [2] - The Global Burden of Disease classification indicates that Alzheimer's disease has escalated from the 12th to the 6th most burdensome disease in the U.S. from 1990 to 2016, based on disability-adjusted life years (DALYs) [2][8] Company Initiatives - Axsome Therapeutics is actively participating in raising awareness and sharing resources related to Alzheimer's disease, alongside advocacy and patient communities [2] - The company is involved in scientific and medical conferences throughout the year to further its mission [2] Research and Development Focus - Axsome Therapeutics is dedicated to addressing central nervous system (CNS) disorders through innovative treatments, focusing on novel mechanisms of action to improve patient outcomes [3][5] - The company's neuroscience portfolio includes FDA-approved treatments for various conditions, including major depressive disorder and narcolepsy [5]